Aviso: para depositar documentos, por favor, inicia sesión e identifícate con tu cuenta de correo institucional de la UCM con el botón MI CUENTA UCM. No emplees la opción AUTENTICACIÓN CON CONTRASEÑA
 

Targeted Sequencing Reveals Low-Frequency Variants in EPHA Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy

dc.contributor.authorApellániz Ruiz, María
dc.contributor.authorTejero Franco, Héctor
dc.contributor.authorInglada Pérez, Lucía Silvia
dc.contributor.authorSánchez Barroso, Lara
dc.contributor.authorGutiérrez Gutiérrez, Gerardo
dc.contributor.authorCalvo, Isabel
dc.contributor.authorCastelo, Beatriz
dc.contributor.authorRedondo, Andrés
dc.contributor.authorGarcía Donás, Jesús
dc.contributor.authorRomero Laorden, Nuria
dc.contributor.authorSereno, María
dc.contributor.authorMerino, María
dc.contributor.authorCurrás Freixes, María
dc.contributor.authorMontero Conde, Cristina
dc.contributor.authorMancikova, Veronika
dc.contributor.authorÅvall Lundqvist, Elisabeth
dc.contributor.authorGreen, Henrik
dc.contributor.authorAl-Shahrour, Fátima
dc.contributor.authorCascón, Alberto
dc.contributor.authorRobledo, Mercedes
dc.contributor.authorRodríguez Antona, Cristina
dc.date.accessioned2024-01-29T15:41:04Z
dc.date.available2024-01-29T15:41:04Z
dc.date.issued2017
dc.description.abstractPurpose: Neuropathy is the dose-limiting toxicity of paclitaxel and a major cause for decreased quality of life. Genetic factors have been shown to contribute to paclitaxel neuropathy susceptibility; however, the major causes for interindividual differences remain unexplained. In this study, we identified genetic markers associated with paclitaxel-induced neuropathy through massive sequencing of candidate genes. Experimental Design: We sequenced the coding region of 4 EPHA genes, 5 genes involved in paclitaxel pharmacokinetics, and 30 Charcot–Marie–Tooth genes, in 228 cancer patients with no/low neuropathy or high-grade neuropathy during paclitaxel treatment. An independent validation series included 202 paclitaxel-treated patients. Variation-/gene-based analyses were used to compare variant frequencies among neuropathy groups, and Cox regression models were used to analyze neuropathy along treatment. Results: Gene-based analysis identified EPHA6 as the gene most significantly associated with paclitaxel-induced neuropathy. Low-frequency nonsynonymous variants in EPHA6 were present exclusively in patients with high neuropathy, and all affected the ligand-binding domain of the protein. Accumulated dose analysis in the discovery series showed a significantly higher neuropathy risk for EPHA5/6/8 low-frequency nonsynonymous variant carriers [HR, 14.60; 95% confidence interval (CI), 2.33–91.62; P ¼ 0.0042], and an independent cohort confirmed an increased neuropathy risk (HR, 2.07; 95% CI, 1.14–3.77; P ¼ 0.017). Combining the series gave an estimated 2.5-fold higher risk of neuropathy (95% CI, 1.46–4.31; P ¼ 9.1 10 4). Conclusions: This first study sequencing EPHA genes revealed that low-frequency variants in EPHA6, EPHA5, and EPHA8 contribute to the susceptibility to paclitaxel-induced neuropathy. Furthermore, EPHA's neuronal injury repair function suggests that these genes might constitute important neuropathy markers for many neurotoxic drugs.
dc.description.departmentDepto. de Enfermería
dc.description.facultyFac. de Enfermería, Fisioterapia y Podología
dc.description.refereedTRUE
dc.description.statuspub
dc.identifier.citationMaría Apellániz-Ruiz, Héctor Tejero, Lucía Inglada-Pérez, Lara Sánchez-Barroso, Gerardo Gutiérrez-Gutiérrez, Isabel Calvo, Beatriz Castelo, Andrés Redondo, Jesús García-Donás, Nuria Romero-Laorden, María Sereno, María Merino, María Currás-Freixes, Cristina Montero-Conde, Veronika Mancikova, Elisabeth Åvall-Lundqvist, Henrik Green, Fátima Al-Shahrour, Alberto Cascón, Mercedes Robledo, Cristina Rodríguez-Antona; Targeted Sequencing Reveals Low-Frequency Variants in EPHA Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy. Clin Cancer Res 1 March 2017; 23 (5): 1227–1235. https://doi.org/10.1158/1078-0432.CCR-16-0694
dc.identifier.doi10.1158/1078-0432.ccr-16-0694
dc.identifier.essn1557-3265
dc.identifier.issn1078-0432
dc.identifier.officialurlhttps://doi.org/10.1158/1078-0432.CCR-16-0694
dc.identifier.urihttps://hdl.handle.net/20.500.14352/96185
dc.issue.number5
dc.journal.titleClinical Cancer Research
dc.language.isoeng
dc.page.final1235
dc.page.initial1227
dc.rights.accessRightsopen access
dc.subject.cdu61
dc.subject.cdu575:61
dc.subject.keywordEPHA genes
dc.subject.keywordPaclitaxel
dc.subject.keywordPeripheral neuropathy
dc.subject.ucmCiencias Biomédicas
dc.subject.ucmGenética médica
dc.subject.unesco24 Ciencias de la Vida
dc.titleTargeted Sequencing Reveals Low-Frequency Variants in EPHA Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy
dc.typejournal article
dc.type.hasVersionAM
dc.volume.number23
dspace.entity.typePublication
relation.isAuthorOfPublication18889f7c-d57c-4837-a726-3a5d71756d3d
relation.isAuthorOfPublication4d11dbbf-1deb-40c5-bc98-c9271b13cf39
relation.isAuthorOfPublication656421b3-1a98-4c54-8f7a-6ac32e278bbb
relation.isAuthorOfPublication.latestForDiscovery4d11dbbf-1deb-40c5-bc98-c9271b13cf39

Download

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
Targeted_Sequencing-VoR.pdf
Size:
552.15 KB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
Targeted_sequencing-AM.pdf
Size:
1.62 MB
Format:
Adobe Portable Document Format

Collections